|Table of Contents|

Treatment of refractory high-grade B-cell lymphoma by immune checkpoint inhibitors combined with chemotherapy：A case report and literature review

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 03
Page:
475-479
Research Field:
Publishing date:

Info

Title:
Treatment of refractory high-grade B-cell lymphoma by immune checkpoint inhibitors combined with chemotherapy：A case report and literature review
Author(s):
LIU Xuanyong1; 2; GUO Zhi1; 2; CHEN Lina1; ZHANG-YI Huizhi1; LI Xumian1; CHEN Xiao1; WANG Qiang2
1.Department of Hematology & Oncology，National Cancer Center/National Clinical Research Cancer for Cancer/Cancer Hospital & Shenzhen Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College，Guangdong Shenzhen 518116，China；2.Medical College，Wuhan University of Science and Technology，Hubei Wuhan 430065，China.
Keywords:
refractory; high-grade B-cell lymphoma; immune checkpoint inhibitors; chemotherapy
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2021.03.025
Abstract:
Objective：To retrospective analyse the efficacy of immune checkpoint inhibitors combined with chemotherapy in an elderly patient with refractory high-grade B-cell lymphoma(non-specific).Methods：Analyze the treatment of this case to investigate the effect of immune checkpoint inhibitors combined with chemotherapy on refractory high-grade B-cell lymphoma，and review in conjunction with relevant literature.Results：This elderly patient with high-grade B-cell lymphoma(non-specific) progressed after multiple courses of chemotherapy.Due to factors such as basic diseases，comorbidities，and tolerance to chemotherapy，the choice of subsequent chemotherapy options was limited and the efficacy was poor.After treating by immune checkpoint inhibitors combined with chemotherapy，the patient's lesions turned to be complete remission，and there was no significant treatment-related adverse reaction.No disease progression time was more than six months.Conclusion：Immune checkpoint inhibitors combined with chemotherapy is one of the effective options for the treatment of refractory high-grade B-cell lymphoma.

References:

[1]JESIONEK-KUPNICKA D，BRAUN M，ROBAK T，et al.A large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification［J］.Adv Clin Exp Med，2019，28(10)：1359-1365.
[2]CROMBIE JL，ARMAND P.Diffuse large B-cell lymphoma and high-grade B-cell lymphoma：Genetic classification and its implications for prognosis and treatment［J］.Surg Oncol Clin N Am，2020，29(1)：115-125.
[3]BROCCOLI A，CASADEI B，CHIAPPELLA A，et al.Lenalidomide in pretreated patients with diffuse large B-cell lymphoma：An italian observational multicenter retrospective study in daily clinical practice［J］.Oncologist，2019，24(9)：1246-1252.
[4]MARTIN A，REDONDO AM，DLOUHY I，et al.Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma：A phase Ⅰb study from GELTAMO group［J］.Br J Haematol，2016，173(2)：245-252.
[5]NOVO M，CASTELLINO A，NICOLOSI M，et al.High-grade B-cell lymphoma：How to diagnose and treat［J］.Expert Rev Hematol，2019，12(7)：497-506.
[6]LI S，LIN P，MEDEIROS LJ.Advances in pathological understanding of high-grade B cell lymphomas［J］.Expert Rev Hematol，2018，11(8)：637-648.
[7]MARUYAMA D.Treatment strategy for high-grade B-cell lymphoma［J］.Rinsho Ketsueki，2018，59(10)：2109-2116.
[8]LEKAKIS LJ，MOSKOWITZ CH.The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma in the era of CAR-T cell therapy［J］.Hemasphere，2019，3(6)：e295.
[9]AGARWAL S，WEIDNER T，THALHEIMER FB，et al.In vivo generated human CAR T cells eradicate tumor cells［J］.Oncoimmunology，2019，8(12)：e1671761.
[10]LOCKE FL，GHOBADI A，JACOBSON CA，et al.Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma(ZUMA-1)：a single-arm，multicentre，phase Ⅰ-Ⅱ trial［J］.Lancet Oncol，2019，20(1)：31-42.
[11]LEE HT，LEE JY，LIM H，et al.Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab［J］.Sci Rep，2017，7(1)：5532.
[12]WARTEWIG T，RULAND J.PD-1 tumor suppressor signaling in T cell lymphomas［J］.Trends Immunol，2019，40(5)：403-414.
[13]GU L，KHADAROO PA，SU H，et al.The safety and tolerability of combined immune checkpoint inhibitors(anti-PD-1/PD-L1 plus anti-CTLA-4)：A systematic review and meta-analysis［J］.BMC Cancer，2019，19(1)：559.
[14]BAIR SM，STRELEC LE，FELDMAN TA，et al.Outcomes and toxicities of programmed death-1(PD-1) inhibitors in Hodgkin lymphoma patients in the united states：A real-world，multicenter retrospective analysis［J］.Oncologist，2019，24(7)：955-962.
[15]NIJLAND M，VAN MEERTEN T，SEITZ A，et al.Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma［J］.Ann Hematol，2018，97(5)：905-907.
[16]HE R，DING W，VISWANATHA DS，et al.PD-1 expression in chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SLL) and large B-cell richter transformation(DLBCL-RT)：A characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness［J］.Am J Surg Pathol，2018，42(7)：843-854.
[17]HAWKES EA，GRIGG A，CHONG G.Programmed cell death-1 inhibition in lymphoma［J］.The Lancet Oncology，2015，16(5)：e234-245.
[18]KIYASU J，MIYOSHI H，HIRATA A，et al.Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma［J］.Blood，2015，126(19)：2193-2201.
[19]HU LY，XU XL，RAO HL，et al.Expression and clinical value of programmed cell death-ligand 1(PD-L1) in diffuse large B cell lymphoma：A retrospective study［J］.Chin J Cancer，2017，36(1)：94.
[20]EMENS LA，MIDDLETON G.The interplay of immunotherapy and chemotherapy：Harnessing potential synergies［J］.Cancer Immunol Res，2015，3(5)：436-443.

Memo

Memo:
深圳市卫生系统科研项目（编号：SZLY2018003)；白求恩医学基金［编号：BQE-TY-SSPC(1)-S-08］
Last Update: 2020-12-31